Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chlorpheniramine + cimetidine
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of chlorpheniramine (an H1 antihistamine) and cimetidine (an H2 receptor antagonist). This combination is primarily used in the treatment of chronic idiopathic urticaria (hives) that does not respond adequately to H1 antagonist therapy alone. The dual blockade of both histamine H1 and H2 receptors provides more effective relief of symptoms including itching and hive formation.
02
Targets
HRH4 (Histamine H4 receptor)HRH2 (Histamine H2 Receptor)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on chlorpheniramine + cimetidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chlorpheniramine + cimetidine.